Skip to content

EBIT at other companies

Veracyte logo
VeracyteVCYT
$22.65M+680%
Personalis, Inc. logo
Personalis, Inc.PSNL
-$32.16M-81.7%
NeoGenomics logo
NeoGenomicsNEO
-$18.24M+34.4%
Fulgent Genetics, Inc. logo
Fulgent Genetics, Inc.FLGT
-$34.62M-74.9%
Cogent Biosciences, Inc. logo
Cogent Biosciences, Inc.COGT
-$103.61M-38.3%
Labcorp Holdings logo
Labcorp HoldingsLH

Other financials

Income statement

See full
Revenue$83.7M-4.9%
Gross profit$63.1M-11.8%
Operating income-$18.4M+34.1%
Net income-$14.5M+43.8%
EPS (diluted)-$0.49+45.6%

Balance sheet

See full
Cash & equivalents$63.8M-28.9%
Total debt$36.7M+42.1%
Total equity$461.4M+4.8%
Total assets$547.8M+9.2%

Cash flow

See full
Operating cash flow-$22.1M-267%
CapEx$12.5M+163%
Free cash flow-$34.6M-221%

Valuation

See full
Market cap$694.86M+29.9%
Enterprise value$667.82M+41.8%
P/S+0.5×

Profitability

See full
Gross margin77.9%-4.1pp
Operating margin-9.8%-30.8pp
Net margin-3.8%-10.2pp
FCF margin1.3%-10.7pp

Returns & leverage

See full
Return on equity-2.8%-10.6pp
Debt / equity0.1×0.0×
Current ratio6.7×-2.6×

Where this comes from

Calculated from Castle Biosciences’s reported figures.

The official record: Castle Biosciences’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Castle Biosciences's ebit.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Castle Biosciences's EBIT?
Castle Biosciences (CSTL) reported EBIT of -$18.41M in Q1 2026.
How has Castle Biosciences's EBIT changed year-over-year?
Castle Biosciences's EBIT increased by 34.1% year-over-year, from -$27.93M to -$18.41M.
What is the long-term trend for Castle Biosciences's EBIT?
Over 4 years (2021 to 2025), Castle Biosciences's EBIT has grown at a 1.7% compound annual growth rate (CAGR), from -$40.08M to -$42.81M.
What does EBIT mean?
Earnings before interest and taxes — the profit from the business before financing cost and tax. Uses reported operating income where a company reports it; otherwise pre-tax income plus interest expense. Lets companies be compared on earning power independent of capital structure.